* Targeting IL-33 in COPD: Who Benefits and What Remains Unknown  HCPLive
* Physician Views In-Depth: Tozorakimab set to both challenge and grow the COPD market  FirstWord Pharma
* IL-33 Inhibition Reduces COPD Exacerbations in Phase III Trials  EMJ
* Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD  HCPLive
* The Duality of IL-33 in COPD, With Francesca Polverino, MD, PhD  HCPLive
http://dlvr.it/TWF6TF